Equibles does not estimate personal net worth.
Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.
Get JAZZ alertsPhilip Johnson is recorded as CFO at Jazz Pharmaceuticals plc (JAZZ). The newest filing on record that lists Philip Johnson as CFO at Jazz Pharmaceuticals plc (JAZZ) is dated June 14, 2024. Jazz Pharmaceuticals plc reported in an 8-K filed February 21, 2024 that Philip Johnson was appointed Executive Vice President and Chief Financial Officer, effective March 1, 2024. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $7,544,473 for Philip Johnson in fiscal 2025, including a base salary of $741,346. Disclosed compensation is on record for 2 fiscal years. Philip Johnson has spoken on 11 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jazz Pharmaceuticals plc includes Bruce Cozadd (CEO and Board Member), Renee D. Gala (CEO), Renee Gala (CEO, COO and Board Member) and 7 others.
“On February 21, 2024, Jazz Pharmaceuticals plc (the "Company") announced the appointment of Philip Johnson as the Company's Executive Vice President and Chief Financial Officer, effective as of March 1, 2024.”
“Turning to our financial results for the quarter, I'll start with high-level comments on our non-GAAP-adjusted P&L, as shown on slide 17.”
“Before diving into the financials for the quarter, I'd like to underscore our consistent progress delivering on our rare disease strategy. Our commercial organization is firing on all cylinders, and we're making targeted investments to continue our momentum.”
“I'll start with high-level comments on our non-GAAP-adjusted P&L, as shown on slide 17.”
“I'll start with our top-line results on slide 19. Please note that our full financial results are available in today's press release and 10K. In the fourth quarter of 2025, we achieved record total revenues of $1.2 billion, with Zywave, Zepzelka, and Rylees all posting their highest-ever revenue quarter.”
“I'll start on Slide 16 with our top line financial results. As a reminder, our full financial results are available in our press release and in our 10-Q. During the third quarter of 2025, we generated $1.126 billion in total revenues.”
Start not stated–present
Last confirmed June 14, 2024
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President and CFO | $741,346 | $7,544,473 |
| 2024 | Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President and CFO | $581,539 | $5,243,445 |
